• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Diseases
mycetoma icon

Mycetoma

Developing safer treatments to prevent disability

Home > Diseases
mycetoma icon

Mycetoma

Developing safer treatments to prevent disability

  • Overview
  • Facts
  • Projects & achievements
  • Target product profile

We ran the world’s first clinical trial for mycetoma. Now we are working to discover and develop new treatments that can prevent disability while improving access to existing treatments.

Mycetoma is a slow-growing infection that destroys skin, muscle, and bone. Primarily affecting the feet and legs, it most likely begins after a cut or thorn prick allows fungi or bacteria from the soil to enter the body. The fungal form of the disease, known as eumycetoma, is particularly devastating and can cause severe disfigurement and disability, and result in stigma, social isolation, and mental health difficulties. While current treatments are effective when combined with surgery, they need to be taken for as long as one year, can cause side effects, and are often inaccessible to people living in remote and resource-constrained settings.

Icon interrogation point

Global burden is unknown

Icon parasite
of mycetoma cases worldwide are fungal
0 %
DOWNLOAD FACTSHEET
SEE DISEASE FACTS

‘This treatment helps reduce the pain and swelling, but for how long will I keep taking these pills? Is there another way to end my suffering? I wish the treatment could be shorter and more effective.’

Erot, a 49-year-old mycetoma patient from Katong’un village in Turkana County, Kenya
READ MORE

What we have achieved

Together with partners, we successfully advocated for mycetoma to be added to the World Health Organization (WHO) list of neglected tropical diseases (NTDs) in 2016. The following year, we ran the world’s first clinical trial for fungal mycetoma – bringing a new treatment option closer to patients in under-resourced settings.

What we are doing for people living with mycetoma

While working with partners to register and expand access to existing but often unavailable drugs in mycetoma-endemic countries, our teams are continuing to advance research into new potential treatments, close knowledge gaps, and better understand the burden and impact of the disease across the ‘mycetoma belt’.

Read more in our Annual Report
SEE TARGET PRODUCT PROFILE
Loading…
Clinical trials

Fosravuconazole

The world’s first clinical trial for mycetoma treatment. Run at the world’s only specialized centre for mycetoma, located in Khartoum, Sudan, this study tested Eisai’s fosravuconazole against the current standard treatment, itraconazole, which is expensive, must be dosed twice a day for a year, and taken with food.

Registration & access

New mycetoma treatments

Ensuring access to safe, effective, affordable treatments. We are working to expand access to treatment and to better understand the burden of mycetoma in endemic areas.

Translational research

Mycetoma Translational platform

The Mycetoma Translational Platform aims to establish a suitable pathway to evaluate and advance new mycetoma drug candidates towards clinical development. DNDi and its partners at Erasmus Medical Centre and the University of Antwerp initiated the development of an in vivo model in early 2026.

see all projects

Mycetoma news & resources

Loading…
filter by
ALL
News
Press releases
Publications
Scientific articles
Statements
Stories
Videos
Viewpoints
Pictures of patients waiting at the Mycetoma Research Center in Sudan
Stories
20 Aug 2026

Mycetoma at 10: What recognition made possible

Viewpoints
30 Jul 2026

Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases

Stat News
Stories
16 Jul 2026

Annie Liang: How students’ advocacy helped bring mycetoma out of the shadows

Publications
16 Jul 2026

DNDi 2025 Annual Report

See all news

Making medical history for neglected patients

We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them

Chagas disease

Causes heart and vital organ damage, after people are bitten by blood-sucking bugs

We delivered the first-ever treatment for children; now we’re searching for new drug candidates and working to boost access to care

Patient medical examination

Cryptococcal meningitis

Without treatment, deadly for thousands of people with advanced HIV

We’re working to improve access to life-saving treatments and developing an easier-to-use formulation

Cutaneous leishmaniasis

Leaves disfiguring, life-long scars that lead to severe social stigma

We’re working to develop safer, shorter treatments for this disabling disease

Dengue

Rapidly spreading climate-sensitive disease with no specific treatment

We’re building a global partnership with dengue-endemic countries to develop a first treatment

Hepatitis C

Millions are left without treatment even though effective drugs exist

We’ve delivered a treatment as simple, safe, and effective as the best drugs available today – at a fraction of the cost 

Mycetoma

Often ends in amputation​, after people get infected from stepping on a thorn

We conducted the world’s first trial for an alternative to current treatments, which are toxic and difficult to administer

Paediatric HIV

Without treatment, half of children die before their second birthday

We’ve developed a strawberry-flavoured treatment to meet the needs of children long neglected by the global HIV response

Healthcare workers in a hospital

Pandemic preparedness and response

COVID-19 threw longstanding global health injustices into stark relief

We’re conducting research for new drugs before the next pandemic strikes and advocating for equitable innovation and access

Parasitic worms

Cause debilitating illness, social exclusion, and long-term disability

We’re working across multiple diseases to develop missing cures that can prevent lasting harm

Sleeping sickness

Transmitted by the bite of a tsetse fly and causes severe neurological disorders

We delivered a revolutionary new drug to replace toxic treatments, and have ongoing trials to eliminate this disease

Visceral leishmaniasis

Is one of the world’s biggest parasitic killers, spread by the bites of sandflies

We’re working to develop a new generation of treatments to replace drugs that are painful, ineffective, and cause side effects

Chagas disease

Cryptococcal meningitis

Cutaneous leishmaniasis

Dengue

Hepatitis C

Mycetoma

Paediatric HIV

Pandemic preparedness and response

Parasitic worms

Sleeping sickness

Visceral leishmaniasis

VIEW ALL DISEASES

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Youtube Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license